GeneTex engages RNA interference technology to validate antibody specificity
At GeneTex, we use an shRNA-mediated RNAi protocol employing a lentiviral expression plasmid optimized for the expression of shRNAs. Once transported into the nucleus, the plasmid directs transcription of the shRNA that is subsequently processed like the miRNAs described above. This makes shRNA more efficient. In addition, the knockdown is more stable over time as the shRNA is constantly expressed. Interestingly, only a few copies of the shRNA-expressing vector need to be integrated into the cell's genome in order to maintain knockdown. This decreases the risk of off-target effects, which is a more prominent problem with transfected siRNAs at their higher introduced concentrations.
GeneTex complements these efforts with CRISPR/Cas9-mediated KO cell lines
GeneTex will continue to expand its utilization of shRNA as a key component of its antibody validation program. In addition, we will incorporate other methodologies to guarantee the specificity of our products, including application of CRISPR/Cas9 technology. Made possible by our collaborative relationship with the genome editing technology company EdiGene, GeneTex will use lysates from EdiGene’s knockout (KO) cell lines to definitively demonstrate antibody specificity. At GeneTex, we understand the importance of quality reagents to your research. We are committed to providing best-in-class reagents and leading the research antibody industry in antibody validation.